BIODLINK-B(01875) issues 13.35 million shares of bonus shares.
Dongyao Pharmaceutical-B (01875) announced that on December 19, 2025, the board of directors has approved the granting of a total of 13.35 million restricted stock units under the 2024 Restricted Stock Incentive Plan, with each unit priced at HK$0.6.
BIODLINK-B (01875) announced that on December 19, 2025, the board of directors has decided to grant a total of 13.35 million restricted stock units under the 2024 Restricted Stock Award Plan, with each unit being awarded at a price of HKD 0.6 per share.
Related Articles
.png)
IPO news | Keen Gene submits application to Hong Kong Stock Exchange
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.
China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.
IPO news | Keen Gene submits application to Hong Kong Stock Exchange
JACOBIO-B(01167) subsidiary enters into licensing and collaboration agreement with AstraZeneca to develop and commercialize the pan-KRAS inhibitor JAB-23E73.
China Securities Co., Ltd.: Three clues for A-share investment at the end of the year and the beginning of the year.
